78 related articles for article (PubMed ID: 32133584)
1. Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
Vandenbossche J; Jessner W; van den Boer M; Biewenga J; Berke JM; Talloen W; De Zwart L; Snoeys J; Vandyck K; Fry J; Yogaratnam J
Adv Ther; 2020 Apr; 37(4):1703. PubMed ID: 32133584
[TBL] [Abstract][Full Text] [Related]
2. Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle.
Lahlali T; Berke JM; Vergauwen K; Foca A; Vandyck K; Pauwels F; Zoulim F; Durantel D
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012770
[TBL] [Abstract][Full Text] [Related]
3. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus.
Berke JM; Dehertogh P; Vergauwen K; Van Damme E; Mostmans W; Vandyck K; Pauwels F
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584155
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV).
Vandyck K; Rombouts G; Stoops B; Tahri A; Vos A; Verschueren W; Wu Y; Yang J; Hou F; Huang B; Vergauwen K; Dehertogh P; Berke JM; Raboisson P
J Med Chem; 2018 Jul; 61(14):6247-6260. PubMed ID: 29906396
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects.
Katz LB; Gambale JJ; Rothenberg PL; Vanapalli SR; Vaccaro N; Xi L; Polidori DC; Vets E; Sarich TC; Stein PP
Clin Pharmacol Ther; 2011 Nov; 90(5):685-92. PubMed ID: 21975348
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B Virus Capsid Completion Occurs through Error Correction.
Lutomski CA; Lyktey NA; Zhao Z; Pierson EE; Zlotnick A; Jarrold MF
J Am Chem Soc; 2017 Nov; 139(46):16932-16938. PubMed ID: 29125756
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.
Yuen MF; Gane EJ; Kim DJ; Weilert F; Yuen Chan HL; Lalezari J; Hwang SG; Nguyen T; Flores O; Hartman G; Liaw S; Lenz O; Kakuda TN; Talloen W; Schwabe C; Klumpp K; Brown N
Gastroenterology; 2019 Apr; 156(5):1392-1403.e7. PubMed ID: 30625297
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.
Huntjens DRH; Ouwerkerk-Mahadevan S; Brochot A; Rusch S; Stevens M; Verloes R
Clin Pharmacokinet; 2017 Nov; 56(11):1331-1342. PubMed ID: 28238203
[TBL] [Abstract][Full Text] [Related]
10. Correction: omitted author.
Fathman CG
Science; 1993 Apr; 260(5106):280. PubMed ID: 17838233
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
[TBL] [Abstract][Full Text] [Related]
12. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
Ren Q; Liu X; Luo Z; Li J; Wang C; Goldmann S; Zhang J; Zhang Y
Bioorg Med Chem; 2017 Feb; 25(3):1042-1056. PubMed ID: 28082068
[TBL] [Abstract][Full Text] [Related]
13. Correction to: Decisional Balance Inventory (DBI) Adolescent Form for Smoking: Psychometric Properties of the Persian Version.
Khazaee-Pool M; Pashaei T; Ponnet K; Jafari F; Alizadeh R
BMC Public Health; 2017 Nov; 17(1):919. PubMed ID: 29191196
[TBL] [Abstract][Full Text] [Related]
14. Correction to: Epidemiology of chronic hepatitis B virus in Ireland using routinely collected surveillance and administrative data, 2004-2014.
van Gemert CE; Murphy N; Mitchell TA; Hellard ME; Thornton L
Ir J Med Sci; 2018 Aug; 187(3):813. PubMed ID: 29322295
[TBL] [Abstract][Full Text] [Related]
15. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects.
van der Ark PD; Golor G; van Nueten L; Nandy P; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1330-1340. PubMed ID: 30182786
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly.
Wu S; Zhao Q; Zhang P; Kulp J; Hu L; Hwang N; Zhang J; Block TM; Xu X; Du Y; Chang J; Guo JT
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566379
[TBL] [Abstract][Full Text] [Related]
17. Erratum: Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer's Disease.
Peter Cao, Nady Braidy, Martin Zarka, Jeffrey Welch and Wallace Bridge
Curr Alzheimer Res; 2016 Aug; 13(10):1198. PubMed ID: 27855601
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Learnings from a Double-Blind, Randomized, Placebo-Controlled, Sequential Group First-in-Human Study of the TRPV1 Antagonist, JNJ-38893777, in Healthy Men.
Manitpisitkul P; Mayorga A; Shalayda K; De Meulder M; Romano G; Jun C; Moyer JA
Clin Drug Investig; 2015 Jun; 35(6):353-63. PubMed ID: 25894894
[TBL] [Abstract][Full Text] [Related]
19. Author Correction: RNAs coordinate nuclear envelope assembly and DNA replication through ELYS recruitment to chromatin.
Aze A; Fragkos M; Bocquet S; Cau J; Méchali M
Nat Commun; 2018 Feb; 9(1):581. PubMed ID: 29402910
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation.
Mani N; Cole AG; Phelps JR; Ardzinski A; Cobarrubias KD; Cuconati A; Dorsey BD; Evangelista E; Fan K; Guo F; Guo H; Guo JT; Harasym TO; Kadhim S; Kultgen SG; Lee ACH; Li AHL; Long Q; Majeski SA; Mao R; McClintock KD; Reid SP; Rijnbrand R; Snead NM; Micolochick Steuer HM; Stever K; Tang S; Wang X; Zhao Q; Sofia MJ
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
